

# CURRICULUM VITAE

**Name:** Lucio Crinò

**Address:**

**Date of Birth:**

**E-mail:**

---

## EDUCATION and APPOINTMENTS

- Classical High School diploma achieved at the High School “S.Ignazio” of Messina on 28/07/1964 with mark 8/10
- Graduated in Medicine and Surgery on 28/07/1970 at the University of Perugia with mark 110/110 cum laude
- Diploma of Specialist in Disease of the Cardiovascular System achieved on 22/07/1974 at the University of Perugia with mark 50/50 cum laude
- Diploma of Oncology Specialist achieved on 22/07/1977 at the University of Pavia with mark 50/ 50
- Diploma of Specialist in Internal Medicine achieved on 04/11/1983 at the University of Perugia with mark 50/50 cum laude
- “Guest Worker” at the Experimental Chemotherapy Laboratory of the National Cancer Institute of Bethesda (USA) from August 1974 to July 1975
- Medical Assistant at the 3 ex ULSS n.3 Perugia:
  - From 08/04/1976 to 30/06/1976 Medical Assistant at the Medicine and Chemotherapy Department with a temporary work contract;
  - From 13/02/1995 to 05/12/1996 Employee of the Azienda Ospedaliera of Perugia assigned at the Medical Oncology Department with the 1° Managerial Level Line A of the Health Role

Previous position: since September 1998 Head of the Medical Oncology of the Medical Oncology of the Bellaria Hospital-Bologna-Italy.

Current position: from 01-07-2005 to 02-9-2016 Head of Medical Oncology Division of the S. Maria della Misericordia Hospital – Perugia – Italy.

From 2012 to 2015 Head Onco Hematology Dept at S. Maria della Misericordia Hospital and Perugia University - Italy

From July 2014 to 2016 Professor of Oncology at School Medicine Perugia University – Italy

Since 2017 up to now Consultant for Thoracic Oncology at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

## **TEACHING, CONSULTING ACTIVITIES, RESEARCH EXPERIENCE-MEMBERSHIP**

He attended as “Clinical Observer” the “Solid Tumor Service of Memorial Sloan-Kettering Cancer Center” of New York from 29 May to 11 June 1986

He attended the Medical Oncology Branch of the National Cancer Institute of Bethesda (USA) from 16 to 27 June 1986

He attended as “Clinical Observer” the “Solid Tumor Service” of Memorial Hospital of New York frp, 24 to 31 May 1987

Member of AIOM-Italian Association of Medical Oncology

Member of ESMO-European Society for Medical Oncology

Member of ASCO-American Society of Clinical Oncology

Member of the IASLC-International Association for Study of Lung Cancer

Meldola, 27<sup>th</sup> November 2018

## List of publications in the last 2 years

Frequency of actionable alterations in epidermal growth factor receptor (*EGFR*) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR).

Chiadini E, Canale M, Delmonte A, Dazzi C, Casanova C, Capelli L, Mariotti M, Papi M, Gamboni A, Puccetti M, Bravaccini S, Dubini A, Calistri D, Crinò L, Ulivi P.

J Thorac Dis. 2018 Aug;10(8):4858-4864. doi: 10.21037/jtd.2018.07.22.

PMID: 30233859

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.

Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13.

PMID: 30014881

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

De Giorgi U, Carteni G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2018 Jun 29. doi: 10.1111/bju.14461. [Epub ahead of print]

PMID: 29956884

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

PMID: 29942662

Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.

Bronte G, Bravaccini S, Bronte E, Burgio MA, Rolfo C, Delmonte A, Crinò L.

Biol Rev Camb Philos Soc. 2018 Nov;93(4):1735-1746. doi: 10.1111/brv.12416. Epub 2018 Apr 19.

PMID: 29671943

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.

Ricciuti B, De Giglio A, Mecca C, Arcuri C, Marini S, Metro G, Baglivo S, Sidoni A, Bellezza G, Crinò L, Chiari R.

Med Oncol. 2018 Apr 17;35(5):72. doi: 10.1007/s12032-018-1133-4. Review.

PMID: 29666949

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.  
Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.  
PMID: 29545095

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, **Crino L**, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leigh N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C.  
ESMO Open. 2017 Jan 13;1(6):e000118. doi: 10.1136/esmooopen-2016-000118. eCollection 2016.  
PMID: 29435365

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G Jr, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L.  
Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041.  
PMID: 29408986

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.  
Clin Lung Cancer. 2018 Jul;19(4):301-314. doi: 10.1016/j.clcc.2017.12.010. Epub 2017 Dec 22.  
Review.  
PMID: 29396237

Perspectives in small cell lung cancer: is something moving?

Crinò L, Delmonte A.  
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S47-S50. doi: 10.21037/tlcr.2017.10.12. No abstract available.  
PMID: 29299410

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.

Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC.  
Ann Oncol. 2018 Mar 1;29(3):687-693. doi: 10.1093/annonc/mdx820.  
PMID: 29293889

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.

Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI.

Br J Cancer. 2018 Jan;118(1):38-42. doi: 10.1038/bjc.2017.395. Epub 2017 Nov 16.  
PMID: 29149104

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.

Ludovini V, Chiari R, Tomassoni L, Antonini C, Baldelli E, Baglivo S, Siggillino A, Tofanetti FR, Bellezza G, Hodge KA, Petricoin E, Pierobon M, Crinò L, Bianconi F.  
Oncotarget. 2017 Jun 14;8(47):83343-83353. doi: 10.18632/oncotarget.18480. eCollection 2017 Oct 10.  
PMID: 29137348

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufel M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE.  
J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.  
PMID: 29023213

Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies.

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, **Crino L**, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED.  
J Thorac Oncol. 2017 Dec;12(12):1755-1765. doi: 10.1016/j.jtho.2017.09.1956. Epub 2017 Sep 27.  
Review.  
PMID: 28962947

Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.

Baglivo S, Ludovini V, Sidoni A, Metro G, Ricciuti B, Siggillino A, Rebonato A, Messina S, Crinò L, Chiari R.  
Mayo Clin Proc. 2017 Aug;92(8):1304-1311. doi: 10.1016/j.mayocp.2017.03.022.  
PMID: 28778263

Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.

Ludovini V, Antognelli C, Rulli A, Foglietta J, Pistola L, Eliana R, Floriani I, Nocentini G, Tofanetti FR, Piattoni S, Minenza E, Talesa VN, Sidoni A, Tonato M, Crinò L, Gori S.  
BMC Cancer. 2017 Jul 26;17(1):502. doi: 10.1186/s12885-017-3483-2.  
PMID: 28747156

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.

Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, **Crino L**, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT.

J Thorac Oncol. 2017 Oct;12(10):1552-1560. doi: 10.1016/j.jtho.2017.06.070. Epub 2017 Jul 6.  
PMID: 28689043

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, **Crino L**, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S.

Eur J Cancer. 2017 Sep;82:27-33. doi: 10.1016/j.ejca.2017.05.019. Epub 2017 Jul 10.  
PMID: 28646771

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators.

N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.  
PMID: 28636851

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy.

Ricciuti B, Baglivo S, Paglialonga L, De Giglio A, Bellezza G, Chiari R, Crinò L, Metro G.

Ther Adv Med Oncol. 2017 Jun;9(6):387-404. doi: 10.1177/1758834017702820. Epub 2017 Apr 16.  
Review.

PMID: 28607578

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E.

Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9.  
PMID: 28602779

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J.

JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438.  
PMID: 28492898

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Mok TSK, **Crino L**, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.

Cancer Treat Rev. 2017 Apr;55:181-189. doi: 10.1016/j.ctrv.2017.03.006. Epub 2017 Mar 30.  
Review.

PMID: 28427013

Optimal management of ALK-positive NSCLC progressing on crizotinib.

Metro G, Tazza M, Matocci R, Chiari R, Crinò L.

Lung Cancer. 2017 Apr;106:58-66. doi: 10.1016/j.lungcan.2017.02.003. Epub 2017 Feb 6. Review.

PMID: 28285695